In order to dissect the molecular mechanisms whereby HIV-1 functionally alters or kills CD4+ T lymphocytes, transfected Jurkat cell lines expressing different HIV-1 proteins were established. Cells constitutively expressing functional qpl20 and qp4l showed no direct alterations in their cell growth and did not spontaneously fuse. In contrast, HIV-infected cells or HIV-envelope transfected cells could be induced to form syncytium and die upon co-culture with naive CD4+ cells. Such infected or transfected cells undergoing cell fusion and cell death displayed dramatic alterations in their intracellular signalling pathways as evidenced by changes in tyrosine phosphorylation of intracellular substrates. Blockade of these phosphorylations with an inhibitor of protein tyrosine phosphorylation, herbimycin A, dramatically reduced the cytopathicity associated with HIV-1. While proteins of about 95 and 30 kilodaltons were most dramatically tyrosine phosphorylated during HIV-1 cell fusion, the phosphorylation of the smaller substrate correlated most closely with syncytium formation and cell death. This protein was identified as the cyclin dependent kinase cdc2, a central regulator of cell cycle which is inhibited by tyrosine phosphorylation. The heavy and light chain antibody genes derived from two human anti-HIV envelope qp4l monoclonal cell lines were cloned, sequenced, and functionally expressed in recipient B cell lines. The genes from one of the two monoclonal lines conferred anti-gp4l specificity to transfected cell lines. The heavy and light chain variable region genes from this antibody (98-6) were genetically linked to the T cell receptor (TCR) constant alpha and beta regions, respectively to generate chimeric antibody/TCR genes. when these chimeric TCR genes were expressed in T lymphocytes, they conferred TCR-dependent activation function to the cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000585-03
Application #
3790827
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Porter, Brian O; Shen, Jean; Kovacs, Joseph A et al. (2009) Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. AIDS 23:2015-9
Sereti, Irini; Sklar, Peter; Ramchandani, Meena S et al. (2007) CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. J Infect Dis 196:677-83
Nishimura, Yoshiaki; Igarashi, Tatsuhiko; Buckler-White, Alicia et al. (2007) Loss of naive cells accompanies memory CD4+ T-cell depletion during long-term progression to AIDS in Simian immunodeficiency virus-infected macaques. J Virol 81:893-902
Sakamoto, Norihisa; Tsuji, Kazuhide; Muul, Linda M et al. (2007) Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood 110:501-8
Igarashi, Tatsuhiko; Iyengar, Ranjini; Byrum, Russel A et al. (2007) Human immunodeficiency virus type 1 derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques. J Virol 81:11549-52
Read, Sarah W; Higgins, Jeanette; Metcalf, Julia A et al. (2006) Decreased CD127 expression on T Cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy. J Acquir Immune Defic Syndr 42:537-44
Brann, Terrence W; Dewar, Robin L; Jiang, Min-Kan et al. (2006) Functional correlation between a novel amino acid insertion at codon 19 in the protease of human immunodeficiency virus type 1 and polymorphism in the p1/p6 Gag cleavage site in drug resistance and replication fitness. J Virol 80:6136-45
Lempicki, R A; Polis, M A; Yang, J et al. (2006) Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 193:1172-7
Youle, Mike; Emery, Sean; Fisher, Martin et al. (2006) A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK-Vanguard Study. PLoS Clin Trials 1:e3
Keh, Chris E; Shen, Jean M; Hahn, Barbara et al. (2006) Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients. AIDS 20:361-9

Showing the most recent 10 out of 38 publications